Literature DB >> 30152589

Glycaemic management during the inpatient enteral feeding of people with stroke and diabetes.

A W Roberts1, S Penfold2.   

Abstract

This paper is an abridged and modified version of guidelines produced by the Joint British Diabetes Societies for inpatient care on glycaemic management during the enteral feeding of people with stroke and diabetes. These were revised in 2017 and have been adapted specifically for Diabetic Medicine. The full version can be found at: www.diabetes.org.uk/joint-british-diabetes-society or https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group. Many people have both diabetes and an acute stroke, and a stanv dard approach to the management of people with stroke is the provision of adequate nutrition. Frequently, this involves a period of enteral feeding if there is impaired ability to swallow food safely. There is currently considerable variability in the management of people with diabetes fed enterally after a stroke, and the evidence base guiding diabetes management in this clinical situation is very weak, although poor glycaemic outcomes in people receiving enteral feeding after stroke may worsen recovery and cause harm. The aim of this document is to provide sensible clinical guidance in this area, written by a multidisciplinary team; this guideline had input from diabetes specialist nurses, diabetologists, dietitians, stroke physicians and pharmacists with expertise in this area, and from UK professional organizations. It is aimed at multidisciplinary teams managing people with stroke and diabetes who require enteral feeding. We recognize that there is limited clinical evidence in this area.
© 2018 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30152589     DOI: 10.1111/dme.13678

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  1 in total

1.  Managing hyperglycaemia in inpatients.

Authors:  Shazia Hussain; Myuri Moorthy
Journal:  Clin Med (Lond)       Date:  2021-07       Impact factor: 2.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.